ArticleCureus2026
Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM), being a progressive metabolic disorder, often needs combination therapy for optimal glycaemic control. Metformin is the standard first-line agent, but its efficacy may diminish over time. Ranolazine, an antianginal drug with emerging antihyperglycaemic properties, has shown promise in improving glucose regulation. This study evaluated the efficacy of ranolazine as an add-on therapy to metformin compared with metformin monotherapy.
methodsA quasi-experimental comparative study was conducted in a tertiary care hospital in eastern India. Adults aged 18-75 years with newly diagnosed or metformin-stabilised T2DM (HbA1c 6.5-9%) were enrolled. Group M received metformin 1000 mg once daily, while Group M+R received metformin 1000 mg once daily plus ranolazine (500 mg twice daily, up-titrated to 1000 mg twice daily). Follow-up of patients was conducted for six months, with assessments at baseline, three months, and six months. The primary endpoint was the mean reduction in HbA1c at three months, while secondary endpoints included changes in fasting blood glucose (FBG), post-prandial blood glucose (PPBG), and the need for rescue medication.
resultsOf 120 randomised patients, 54 in Group M and 58 in Group M+R completed the study. At three months, the combination group achieved a significantly greater HbA1c reduction (mean difference 0.25%, p=0.022), with sustained benefit at six months (mean difference 0.23%, p=0.037). FBG and PPBG were significantly lower in the combination group at both three and six months. Regression analysis identified longer diabetes duration, higher LDL, and elevated baseline HbA1c as predictors of HbA1c change. No increased risk of hypoglycaemia was observed.
conclusionRanolazine, when added to metformin, provides incremental and statistically significant improvements in glycaemic control, supporting its potential role as an adjunct therapy in T2DM. Larger, longer-term studies are warranted to confirm durability and cardiovascular benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.